Lexicon Pharmaceuticals
LXRX
146 hedge funds and large institutions have $1.53B invested in Lexicon Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 51 increasing their positions, 39 reducing their positions, and 20 closing their positions.
219% more call options, than puts
Call options by funds: $7.88M | Put options by funds: $2.47M
106.32% more ownership
Funds ownership: 0% → 106.32% (+106%)
31% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 39
30% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 20
1% more funds holding
Funds holding: 144 → 146 (+2)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
24% less capital invested
Capital invested by funds: $2.01B → $1.53B (-$483M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$18.3M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$8.16M |
| 3 |
KCM
Kingdon Capital Management
New York
|
+$6.54M |
| 4 |
State Street
Boston,
Massachusetts
|
+$3.74M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$17.1M |
| 2 |
UBS AM
Chicago,
Illinois
|
-$10.8M |
| 3 |
D.E. Shaw & Co
New York
|
-$9.29M |
| 4 |
BM
Bridger Management
New York
|
-$6.09M |
| 5 |
Two Sigma Investments
New York
|
-$5.13M |
LXRX Hedge Fund Activity: Q4 2016 in Review
146 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q4 2016, worth a combined $1.53B — down 24% from $2.01B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new LXRX positions and 20 closed out — a net gain of 6 holders — while 51 added to existing stakes and 39 trimmed.
The largest buyer was Eagle Asset Management, adding an estimated $18.3M. The largest seller was Arrowstreet Capital, exiting entirely with an estimated $17.1M sold.
- 146 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q4 2016, up from 144 in Q3 2016.
- Funds reported $1.53B of Lexicon Pharmaceuticals stock for Q4 2016, down 24% quarter-over-quarter.
- 26 funds opened new Lexicon Pharmaceuticals positions in Q4 2016 and 20 closed out, a net change of +6 holders.
- The largest Lexicon Pharmaceuticals buyer in Q4 2016 was Eagle Asset Management, an estimated $18.3M added.
- The largest Lexicon Pharmaceuticals seller in Q4 2016 was Arrowstreet Capital, an estimated $17.1M sold.
Based on aggregated 13F filings for Q4 2016.